Regenxbio (RGNX) Total Liabilities (2014 - 2025)

Regenxbio's Total Liabilities history runs 12 years deep, the most recent figure standing at $350.3 million for Q4 2025.

• In Q4 2025, Total Liabilities rose 69.77% year-over-year to $350.3 million; the TTM figure through Dec 2025 stood at $350.3 million (up 69.77% YoY), while the FY2025 annual figure was $350.3 million, up 69.77% from the prior year.
• Total Liabilities was $350.3 million for Q4 2025 at Regenxbio, down from $363.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $367.3 million in Q2 2025 to a low of $206.3 million in Q4 2024.
• Historically, Total Liabilities has averaged $295.6 million across 5 years, with a median of $318.5 million in 2022.
• The sharpest annual moves came in 2021 and 2024: Total Liabilities soared 642.14% in 2021, then decreased 21.31% in 2024.
• A 5-year view of Total Liabilities shows it stood at $349.6 million in 2021, then fell by 9.31% to $317.1 million in 2022, then dropped by 17.3% to $262.2 million in 2023, then fell by 21.31% to $206.3 million in 2024, then soared by 69.77% to $350.3 million in 2025.
• The last three Total Liabilities figures came in at $350.3 million (Q4 2025), $363.8 million (Q3 2025), and $367.3 million (Q2 2025), per Business Quant data.